MPD doctors discuss benefits of 2 JAK2 Inhibitors

December 2010

Drs. Ayalew Tefferi and Animesh Pardanani presented data at ASH on the benefits of two drugs currently in clinical trials: TG101348 and CYT387. TG101348 is currently being tested in myelofibrosis patients and has been shown to reduce constitutional symptoms as well as reduction in spleen size and JAK burden in many of the patients. CYT387 is also being tested in myelofibrosis patients and also reduces spleen size as well as helps with symptoms, but also works to reduce the affects of anemia in myelofibrosis patients.

For the original article click here.

Receive updates on the latest MPN news & events.

Find out ways you can help support MPN patients and researchers.

x

NEVER MISS AN UPDATE

Get free, timely information on living with an MPN.

Subscribe